To protect our staff and visitors from COVID-19, OPA office staff will work remotely. We’ll continue to be fully operational to serve our members. Contact us at 416-441-0788 or 1-877-341-0788 or mail@opatoday.com.

Publications

  • New Drugs/Drug News 2012, Volume 30, No. 3

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    Fidaxomicin (Dificid – Optimer Pharmaceuticals Canada, Inc.):a new antibacterial agent for Clostridium difficile infection

  • New Drugs/Drug News 2012, Volume 30, No. 2

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    Clinical Update: Treatment of Acne Vulgaris

  • New Drugs/Drug News 2012, Volume 30, No. 1

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    Apixaban (Eliquis – Bristol-Myers Squibb Canada & Pfizer Canada Inc.): A New Oral Anticoagulant

  • Annual Report 2011-12

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    A look at the activities of the Ontario Pharmacists Association over the past Board year (June 2011 – June 2012).

  • Full Financial Statements 2012

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    Full audited financial statements for the year ending December 31, 2012.

  • Fall 2012

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    Therapeutic Options: Focus on Parkinson’s Disease

  • Summer 2012

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    Robbery prevention in a post-Oxycontin® world; Therapeutic Options: Update on Osteoporosis; plus much more

  • New Drugs/Drug News 2012, Volume 29, No. 4

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    Boceprevir (Victrelis – Merck Canada Inc.) and Telaprevir (Incivek – Vertex Pharmaceuticals [Canada] Inc.) for Chronic Hepatitis C Virus Infection

  • Summer 2012

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    Therapeutic Options: Focus on Osteoporosis

  • Spring 2012

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    Making a case for pharmacists’ role in injection and minor ailment programs; Therapeutic Options: Focus on Alzheimer’s Disease; plus much more.

Back to top